Cell captives can help companies achieve a range of goals, and their use cases and utilization rates have been increasing in recent years. While more companies are adopting a cell captive structure, that doesn’t make them any less complicated. Accounting guidance and other regulatory factors often prohibit organizations from aligning the financial reporting of their cell captive with the corporate objectives of the entity.
In this whitepaper, co-authored by Karin Landry, Managing Partner of Spring and Josh Partlow, Partner at Johnson Lambert, will walk you through the evolution of cell captive structures, and provide guidance on financial reporting options and how to address GAAP guidance.
Download the white paper to get a brief history of cell captives, understand the different structures available, insight into the decision to consolidate or not, how variable interest entities come into play and more. We’ll use a sample balance sheet to illustrate these concepts.
Latest posts by Christine Culgin (see all)
- Spring Hits it Big in Captive International’s US Awards - October 6, 2020
- DOL Issues Updated FFCRA Regulations In Light Of Recent Federal Court Decision - September 18, 2020
- Make Better Healthcare Decisions Through Claims Repricing - September 16, 2020
- Spring Short-Listed for 6 Captive Review Awards - August 18, 2020
- Spring Launches 2nd Annual Healthcare Benchmarking Survey - August 12, 2020